Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

By S. Tomlins, Daniel R. Rhodes, S. Perner, S. Dhanasekaran, R. Mehra, Xiao-wei Sun, S. Varambally, Xuhong Cao, J. Tchinda, R. Kuefer and 6 more. Science, 2006

2,614 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0af9abdafc0b287e0e03c3af06d48d0da17522ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. (2007, neutral): “Gene Fusions in Lung Cancer A recent report (Soda et al., 2007) identified EML4-ALK fusions in 6.7% of Japanese patients consistent with growing evidence for chromosomal translocations in solid tumors (Mitelman et al., 2004), particularly prostate cancer (Tomlins et al., 2005).”
The genomic complexity of primary human prostate cancer (2011, neutral): “68 All point mutations (high confidence) 3,898 (1,447) 3,829 (1,430) 3,866 (1,936) 4,503 (2,227) 3,465 (1,831) 5,865 (2,452) 3,192 (1,713)”
Androgen-induced TOP2B mediated double strand breaks and prostate cancer gene rearrangements (2010, background): “The most common of these rearrangements, occurring in nearly 50% of prostate cancers, involves fusion of TMPRSS2 , an androgen regulated gene, with ERG , an ETS transcription factor gene, resulting in activation of the TMPRSS2-ERG fusion oncogene through subversion of androgen signalin”
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort (2007, methodology): “This result confirms our previous finding where 19 of 20 prostate cancer cases with ERG overexpression were shown to have TMPRSS2:ERG rearrangement by sequencing (Tomlins et al., 2005).”
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies (2008, background): “On a larger scale, chromosomal translocations can result in gene regulation by promoters that are sometimes enhanced by steroid hormones”
Identification of Targetable FGFR Gene Fusions in Diverse Cancers (2013, neutral): “In 2005, it was discovered that over 50% of prostate cancers harbor recurrent gene fusions of the androgen-regulated gene TMPRSS2 with ETS transcription factors (7), suggesting that gene fusions/translocations may play a significant role in common epithelial tumors similar to hematologic malignancie”
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. (2006, background): “Male 75 (60) 54 (59) 51 (60) Female 50 (40) 37 (41) 33 (40)”
The molecular taxonomy of primary prostate cancer (2015, background): “In particular, the TMPRSS2-ERG fusion is the most common molecular alteration in prostate cancer (Tomlins et al., 2005), being found in between 40 and 50% of prostate tumor foci, translating to more than 100,000 cases annually in the United States (Tomlins et al., 2009).”
Transcriptome Sequencing Identifies PCAT-1, a Novel lincRNA Implicated in Prostate Cancer Progression (2011, background): “tumor suppressor gene and gain of oncogenic ETS family transcription factor gene fusion”
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo (2010, neutral): “In fact, the most common known cancer-associated translocation is the TMPRSS2-ERG fusion, which introduces a strong androgen receptor (AR)-dependent regulatory element upstream of the ERG gene (Tomlins et al, 2005).”
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate (2009, background): “370" language="eng" relation="no"> Chromosomal translocations involving the ERG locus are frequent events in human prostate cancer pathogenesis; however, the biological role of aberrant ERG expression is controversia”
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer (2007, methodology): “Endogenous expression of 59 fusion partners (normalized to the housekeeping gene GAPDH) was assessed by Q-PCR in LNCaP cells with (1) or without (–) stimulation by the synthetic androgen R1881 (mean (n 5 4) plus s.”